Equities analysts predict that AbbVie Inc (NYSE:ABBV) will report $8.36 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for AbbVie’s earnings. The highest sales estimate is $8.57 billion and the lowest is $8.28 billion. AbbVie reported sales of $7.74 billion during the same quarter last year, which would suggest a positive year over year growth rate of 8%. The business is expected to announce its next quarterly earnings results on Friday, January 25th.

On average, analysts expect that AbbVie will report full year sales of $32.78 billion for the current year, with estimates ranging from $32.69 billion to $33.02 billion. For the next fiscal year, analysts forecast that the business will report sales of $33.59 billion, with estimates ranging from $33.15 billion to $33.93 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow AbbVie.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, November 2nd. The company reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.13. AbbVie had a return on equity of 2,006.63% and a net margin of 23.50%. The company had revenue of $8.24 billion for the quarter, compared to the consensus estimate of $8.23 billion. During the same quarter in the prior year, the company earned $1.41 earnings per share. AbbVie’s revenue was up 17.7% on a year-over-year basis.

A number of research analysts have weighed in on ABBV shares. BMO Capital Markets reissued a “sell” rating and issued a $78.00 target price on shares of AbbVie in a report on Wednesday, August 22nd. Wolfe Research started coverage on AbbVie in a report on Tuesday, October 23rd. They issued an “underperform” rating on the stock. Zacks Investment Research raised AbbVie from a “hold” rating to a “buy” rating and set a $105.00 target price on the stock in a report on Monday, October 1st. Credit Suisse Group set a $85.00 target price on AbbVie and gave the company a “hold” rating in a report on Friday, November 2nd. Finally, Barclays reissued a “hold” rating and issued a $90.00 target price on shares of AbbVie in a report on Sunday, November 4th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. AbbVie presently has an average rating of “Hold” and an average price target of $103.68.

In other AbbVie news, EVP Henry O. Gosebruch sold 42,450 shares of the company’s stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $90.10, for a total value of $3,824,745.00. Following the completion of the sale, the executive vice president now owns 30,350 shares in the company, valued at $2,734,535. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Laura J. Schumacher sold 94,140 shares of the company’s stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $93.58, for a total value of $8,809,621.20. Following the completion of the sale, the insider now owns 192,398 shares of the company’s stock, valued at approximately $18,004,604.84. The disclosure for this sale can be found here. Corporate insiders own 0.07% of the company’s stock.

Several large investors have recently added to or reduced their stakes in ABBV. Capital International Investors grew its position in shares of AbbVie by 266.4% during the third quarter. Capital International Investors now owns 27,594,648 shares of the company’s stock worth $2,609,902,000 after purchasing an additional 20,063,435 shares in the last quarter. Capital World Investors grew its position in shares of AbbVie by 74.9% during the third quarter. Capital World Investors now owns 25,359,025 shares of the company’s stock worth $2,398,457,000 after purchasing an additional 10,858,432 shares in the last quarter. Matthew Goff Investment Advisor LLC grew its position in shares of AbbVie by 9,165.1% during the third quarter. Matthew Goff Investment Advisor LLC now owns 2,226,305 shares of the company’s stock worth $24,029,000 after purchasing an additional 2,202,276 shares in the last quarter. FMR LLC grew its position in shares of AbbVie by 22.1% during the third quarter. FMR LLC now owns 8,707,454 shares of the company’s stock worth $823,551,000 after purchasing an additional 1,574,495 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. purchased a new stake in shares of AbbVie during the third quarter worth about $133,646,000. Hedge funds and other institutional investors own 69.85% of the company’s stock.

ABBV stock traded down $3.37 during trading on Friday, reaching $86.96. The stock had a trading volume of 6,618,342 shares, compared to its average volume of 7,124,616. AbbVie has a 52 week low of $77.50 and a 52 week high of $125.86. The company has a debt-to-equity ratio of 8.70, a quick ratio of 1.08 and a current ratio of 1.20. The company has a market cap of $136.21 billion, a price-to-earnings ratio of 15.53, a P/E/G ratio of 0.84 and a beta of 1.68.

The business also recently declared a quarterly dividend, which will be paid on Friday, February 15th. Shareholders of record on Tuesday, January 15th will be given a $1.07 dividend. This is a boost from AbbVie’s previous quarterly dividend of $0.96. The ex-dividend date is Monday, January 14th. This represents a $4.28 dividend on an annualized basis and a yield of 4.92%. AbbVie’s dividend payout ratio is presently 68.57%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.

Further Reading: Why is the conference call important?

Get a free copy of the Zacks research report on AbbVie (ABBV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.